Biotech Values

[10nisman]

Healthtrust, and other GPOs, had pricing of WAC - 30% prior to M-enox approval. On the day of approval SNY came down another 1000 basis points to WAC - 40% to Healthtrust members, and as it turns out, most GPOs.

So your saying SNY lowered its pricing an additional 10% (or 14% on a revenue basis) compared to its GPO pricing prior to Sandoz/MNTA approval? I don't see that as an attempt or a willingness to start a price war.

10nis